{"prompt": "['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 43 of 51', 'Study ID RCB: 2020-A00652-37', 'LEO will keep a copy of all documents submitted and an updated list of all submission and', 'approval dates of all documents submitted to the IEC and/or authorities and will provide the', 'Site Responsible with a copy of this list. Copies of the documents will be distributed upon', 'request.', 'None of the data planned to be collected are expected to have any psychological impact on', 'the participants, and the questions posed will be presented in a non-judgmental, objective', \"manner so that the impact on the patient's behaviour and honesty in data reporting is\", 'minimized. The nature of the collected data will not make it possible to track the patients', 'without access to the participant lists and Consent Forms stored at the Study Site. The', 'collection of this data is considered ethically justified, based on these precautions and the', 'following considerations.', 'This study focuses on collecting data on the real-life experience of biologic treated psoriasis', 'patients for up to 56 weeks.', 'It will be a challenge to keep patients motivated to contribute data to the study long-term,', 'but psoriasis patients are generally very willing to share their experience with those lending', 'non-judgmental ears to their experience.', 'The Site Study Responsible must give the patient oral and written information about the study', \"in a form that the patient can understand, and obtain the patient's written consent before\", 'collection of identifiable patient information (hereinafter referred to as personal data). Before', 'consenting, the patient must be given sufficient time to consider and to pose questions. Since', 'the study is observational the consent only concerns the data collection per se and is not', 'consent to any interventional procedure or treatment.', 'The patient must agree that his/her data will be transferred to LEO and processed and stored,', 'and shared with other business partners responsible for Kyntheum in other markets. In', 'addition, the patient must agree that authorized representatives from LEO or local authorities', 'with inspection rights get access to their consent documentation and medical records for', 'quality checks on protocol compliance and the data entries if requested. Written informed', 'consent to use of collected data must always be obtained before collection of any personal,', 'sensitive data. Data erroneously collected from patients for which written consent is not', 'available, will not be included in or will be deleted from the database, as feasible.', 'The patient has the right to withdraw his/her consent at any time without prejudice. In the', 'Informed Consent Form it is stated that if consent is withdrawn, any data collected before', 'withdrawal of consent will be kept. The original, signed Informed Consent Forms must be kept', 'on the Site.', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 44 of 51', 'Study ID RCB: 2020-A00652-37', '11', 'Management and Reporting of Adverse Events and Other', 'Experiences', '11.1Definitions', 'Adverse Event', 'An adverse event (AE) is any untoward medical occurrence in a patient administered a', 'medicinal product and which does not necessarily have to have a causal relationship with this', 'treatment. An adverse event can therefore be any unfavourable and unintended sign (e.g. an', 'abnormal laboratory finding), symptom, or disease temporally associated with the use of a', 'medicinal product, whether or not considered related to the medicinal product.', 'Adverse Drug Reaction', 'An Adverse Drug Reaction (ADR) is a response to a medicinal product which is noxious and', 'unintended. Response in this context means that a causal relationship between a medicinal', 'product and an adverse event is at least a reasonable possibility. ADRs may arise from use of', 'the product within or outside the terms of the marketing authorisation or from occupational', 'exposure.', 'Conditions of use outside the marketing authorisation include off-label use, overdose, misuse,', 'abuse and medication errors', 'Other Experiences', \"Other Experiences (OE) are considered 'non events' which describe the circumstances around\", 'the use of a drug which potentially could cause drug related problems or which could', 'potentially give positive knowledge of a drug. These may or may not be associated with', 'adverse events.', 'These events include but are not limited to: unintended beneficial effects, drug exposure in', 'utero, drug exposure via breast milk, drug exposure before and/or during pregnancy, paternal', 'drug exposure before and/or during pregnancy, occupational exposure, drug overdose or', 'abuse, drug misuse, medication error (including potential and intercepted), off label', 'use/unapproved use, lack of efficacy, loss of efficacy, drug and food interaction, any suspicion', 'of counterfeit product, and suspected transmission of an infectious agent by a medicinal', 'product.', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 45 of 51', 'Study ID RCB: 2020-A00652-37', 'Seriousness', 'A serious ADR or AE is any ADR or AE which results in death, is life threatening, requires', 'inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or', 'significant disability or incapacity, or is a congenital anomaly or birth defect.', 'Life-threatening in this context refers to a reaction in which the patient was at risk of death a', 'the time of the event; it does not refer to an event which hypothetically might have caused', 'death if it was more severe.', 'Medical and scientific judgement should be exercised in deciding whether other situations', 'should be considered serious, such as important medical events that might not be immediately', 'life-threatening or result in death or hospitalisation but might jeopardise the patient or might', 'require intervention to prevent one of the other outcomes listed above.', 'Any suspected transmission of an infectious agent via a medicinal product is considered a', 'serious ADR.', 'Severity', 'Severity is a clinical observation and describes the intensity of the event.', 'Mild:', \"Transient symptoms, no interference with the patient's daily activities\", 'Moderate:', \"Marked symptoms, moderate interference with the patient's daily activities\", 'Severe:', \"Considerable interference with the patient's daily activities.\", 'Causality', 'Possible:A reasonable temporal relationship between the medicinal product', 'administration and the event, and there is no other obvious explanation for the occurrence', 'of the event.', 'Not related: There is evidence for (an) alternative explanation(s) for the event (e.g. the', 'event is explained by one or more of the following:', \"a) the patient's medical condition,\", 'b) a concomitant medication for which the event is labelled, or', 'c) the event occurred prior to the introduction of the medicinal product).', '11.2', \"Physician's responsibility for reporting of Adverse Drug Reactions,\", 'Adverse Events and Other Experiences', 'Physicians and other healthcare professionals involved in the study should report to LEO any', 'AE (including SAEs), OE or pregnancy in patients who are or were treated with Kyntheum', 'within 24 hours of becoming aware of it.', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']", "completion": ""}